Ask about this productRelated genes to: SECTM1 antibody
- Gene:
- SECTM1 NIH gene
- Name:
- secreted and transmembrane 1
- Previous symbol:
- -
- Synonyms:
- K12
- Chromosome:
- 17q25
- Locus Type:
- gene with protein product
- Date approved:
- 1997-10-27
- Date modifiied:
- 2008-07-18
Related products to: SECTM1 antibody
Related articles to: SECTM1 antibody
- Urinary proteomic profiling (UPP) provides insights in disease mechanisms and origin of symptoms. Using UPP, this study aimed at deepening insight in the biology of exercise tolerance. - Source: PubMed
Publication date: 2026/07/30
Liu Chu-HaoMartens Dries SAn De-WeiSiwy JustynaLatosinska AgnieszkaPellicori PierpaoloVerdonschot Job A JAhmed Fozia ZWei Fang-FeiRossignol PatrickPetutschnigg JohannesHeymans StephaneCuthbert Joe JYu Yu-LingGirerd NicolasClark Andrew LVerhamme PeterZhang Dong-YanLi YanNawrot Tim SCleland John GZannad FaiezMischak HaraldStaessen Jan A - Secreted and Transmembrane Protein 1 (SECTM1) is a versatile immunomodulatory protein that exists in both membrane-bound and soluble forms. Initially identified for its interaction with the T-cell receptor CD7, it was primarily regarded as a co-stimulatory molecule restricted to lymphoid signaling. Recent evidence has significantly expanded this paradigm, revealing that SECTM1 serves as a pivotal bridge between innate and adaptive immune responses. Beyond its classic role, SECTM1 interacts with alternative receptors like the glucocorticoid-induced TNFR-related protein to regulate macrophage activity and neutrophilic inflammation. This review highlights a major shift in our understanding of SECTM1: it acts as a multi-systemic regulator that influences the tumor microenvironment, metabolic homeostasis, and tissue regeneration. We systematically delineate the molecular mechanisms by which SECTM1 governs immune cell migration and activation across diverse pathologies, including cancer, cardiovascular disorders, and neurodegenerative diseases. By positioning SECTM1 as a marker of "immune-hot" tumors and a potential early diagnostic biomarker for systemic conditions, this work underscores its emerging clinical potential as a target for precision immunotherapy and regenerative medicine. - Source: PubMed
Publication date: 2026/05/18
Yu WenqingWu YushengDing MingdongGuo LiLiu YingYang PeiqingZhu JingZhou DamingYang YonglinGu Chengjing - Germline genetic susceptibility to pediatric acute lymphoblastic leukemia (pALL) remains incompletely characterized across the allelic spectrum, including ultrarare, high-penetrance cancer-predisposing variants (CPV). - Source: PubMed
Meng XiaoxiChen ChengQin NaMulder Heather LEaston JohnEdmonson Michael NRusch MichaelZhang JinghuiMyers Jason RSpector Logan GTurcotte Lucie MChanock Stephen JYang Jun JNichols Kim EPui Ching-HonXu JianMullighan Charles GHudson Melissa MNess Kirsten KArmstrong Gregory TChatterjee NilanjanIm CindyWang Zhaoming - Polycystic ovary syndrome (PCOS) is a heterogeneous disorder with incompletely understood epigenetic regulation. We investigated the role of N6-methyladenosine (m6A)-related single nucleotide polymorphisms (m6A-SNPs) in PCOS. - Source: PubMed
Publication date: 2026/04/11
Jin MengqiXi SujuanMa Lin - Type 2 diabetes mellitus (T2DM) significantly elevates the risk of tuberculosis (TB); however, early detection in T2DM patients is still insufficient. This study aimed to identify immune-based early-warning biomarkers, develop robust prognostic models, and elucidate the immune-metabolic circuitry underlying the comorbidity of type 2 diabetes and tuberculosis (T2DM-TB). - Source: PubMed
Publication date: 2026/02/26
Ye ZhaoyangBai GuangliangCheng PengPeng CongYang LingZhuang LiLi LinshengLi YufengNi RuiziZhou ShuangAn YajingZhang MingmingTian YuanWang LiangGong Wenping